Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tarsus PharmaceuticalsTARS +1.32%43 3-Year EPS without NRI Growth Rate is 13.90% as of Jun. 2026. GuruFocus rates TARS with a GF Score™ of 43/100 and a GF Value™ of $157.96 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 1,162 Biotechnology companies, Tarsus Pharmaceuticals ranks worse than 53.44% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 13.90% per year.
During the past 5 years, the average EPS without NRI Growth Rate was -1.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 8 years, the highest 3-Year average EPS without NRI Growth Rate of Tarsus Pharmaceuticals was 13.90% per year. The lowest was -70.00% per year. And the median was -9.80% per year.
Tarsus Pharmaceuticals (NAS:TARS) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Tarsus Pharmaceuticals 3-Year EPS without NRI Growth Rate Related Terms
TARS vs VERA, BEAM, KOD: 3-Year EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, Tarsus Pharmaceuticals's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tarsus Pharmaceuticals 3-Year EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tarsus Pharmaceuticals's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Tarsus Pharmaceuticals's 3-Year EPS without NRI Growth Rate falls into.
Tarsus Pharmaceuticals 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 13.90% mean?
Tarsus Pharmaceuticals (TARS) has a 3-Year EPS without NRI Growth Rate of 13.90% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Tarsus Pharmaceuticals and its competitors. According to the industry distribution chart, Tarsus Pharmaceuticals ranks #621 out of 1162 companies in the Biotechnology industry, placing it in the top 53.4%.
Is Tarsus Pharmaceuticals' 3-Year EPS without NRI Growth Rate too high?
Tarsus Pharmaceuticals' current 3-Year EPS without NRI Growth Rate is 13.90%. The Biotechnology industry median 3-Year EPS without NRI Growth Rate is 16.20. Tarsus Pharmaceuticals' value of 13.90% is 14.2% below this industry median. Based on the distribution chart, Tarsus Pharmaceuticals ranks #621 out of 1162 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Tarsus Pharmaceuticals has a GF Score™ of 43/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Tarsus Pharmaceuticals' 3-Year EPS without NRI Growth Rate compare to VERA and BEAM?
According to the Biotechnology industry distribution chart, Tarsus Pharmaceuticals ranks #621 out of 1162 companies for 3-Year EPS without NRI Growth Rate. This places Tarsus Pharmaceuticals in the lower half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 16.20. Tarsus Pharmaceuticals' value of 13.90% is 14.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 16.20, based on 1,162 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tarsus Pharmaceuticals's current 3-Year EPS without NRI Growth Rate of 13.90% is 14.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Tarsus Pharmaceuticals and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 16.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tarsus Pharmaceuticals's current 3-Year EPS without NRI Growth Rate is 13.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tarsus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Tarsus Pharmaceuticals (TARS) is currently considered Significantly Undervalued. The stock's GF Value™ is $157.96, compared to a current price of $71.54 — trading 54.7% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 13.90% and 14.2% below the Biotechnology industry median of 16.20. Tarsus Pharmaceuticals' overall GF Score™ is 43/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Tarsus Pharmaceuticals (TARS), the current 3-Year EPS without NRI Growth Rate is 13.90% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tarsus Pharmaceuticals (TARS) Overvalued in 2026?
Based on GuruFocus' analysis, Tarsus Pharmaceuticals stock appears to be undervalued.
The current stock price of $71.54 is trading 54.7% below its estimated GF Value™ of $157.96.
GuruFocus considers Tarsus Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for TARS:
3-Year EPS without NRI Growth Rate: 13.90%
GF Value™: $157.96 vs. price of $71.54 (54.7% below fair value)
Industry Position: 14.2% below the Biotechnology median (#621 of 1162)
No single metric tells the full story. See the TARS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
43GF Score
Get the complete analysis for TARS
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TARS has been successfully added to your 
